Complementary and alternative medicine (CAM) is used by many cancer patients by themselves. Therefore, we conducted a survey regarding the association between CAM, self-efficacy, and patient activation in adult cancer patients. A standardized questionnaire, consisted of the ASKU, the PAM 13-D, and a structured questionnaire on CAM usage from our own working group, was distributed to 880 potential participants. Six hundred and thirty-nine (639) patients (male 32.9%, female 63.2%; gynecological cancer 41%, gastrointestinal 19.2%, urogenital 15.6%) took part. 60% of all patients used CAM in the last 3 months (biological 73%, holistic 63%, mind–body methods 62%). Higher self-efficacy was associated with higher interest in CAM (p = 0.03), but not usage of CAM, compared to patients with lower self-efficacy (p = 0.099). Higher patient activation was associated with higher interest in CAM (p = 0.004) and usage of CAM (p = 0.012). Patients with higher activation significantly more often used homeopathy (p = 0.007), prayer (p = 0.002), yoga, etc. (p = 0.032), meditation (p = 0.002), low carb or ketogenic diets (p < 0.001) (but not vegan or other cancer diets). Higher patient activation is associated with higher usage of CAM. Focusing on patient activation as a goal in patient–physician relationship will help patients to adhere to a healthy lifestyle and to actively participate in the whole treatment process.
Hinweise
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Complementary and alternative medicine (CAM) is often used by cancer patients [1, 2]. Goals with CAM are diverse. Patients want to strengthen themselves or do something for themselves. They aim at reducing side effects or to boost the immune system. Some use CAM to have better control of the cancer and/or not to leave out a chance [2, 3].
All in all, some CAM methods depend on the patient’s activity, while others are more dependent on a third party.
Anzeige
As CAM is most often initiated by the patient and at least a part of CAM methods depends on the patient’s action, a hypothesis is that CAM usage is a sign of patient activation and reinforces patient’s self-efficacy. If this is true, CAM might provide direct benefits by improving body or mental functions. Additionally, indirect benefits might be an increase in patient empowerment. Yet, as with some CAM methods the patient depends on the physician or expert as much as he/she does on the physician in case of a conventional treatment as radio- or chemotherapy, there are some doubts on this indirect effect at least for part of CAM.
With respect to personal characteristics of the patient and CAM usage, we have conducted several studies before. We did not find any association between the personal traits “Big Five” and CAM usage in general or categories of CAM [4]. In another study, patients using CAM often had a high external locus of control, while we did not find any association to a higher internal locus of control [4, 5]. We addressed the association of CAM and self-efficacy in two surveys as secondary endpoints and found no association [5].
To evaluate the association of CAM usage, self-efficacy, and patient activation in detail, we planned a nationwide survey on adult cancer patients in Germany.
Methods
Questionnaire
The questionnaire was composed of three validated questionnaires: the ASKU (Allgemeine Selbstwirksamkeit Kurzskala) [6], the PAM 13-D (Patient Activation Measure) [7], and the AKKOM (questionnaire on complementary and alternative medicine, developed by the working group Prevention and Integrative Oncology of the German Cancer Society) [2]. The development and testing of the questionnaire has been reported before [8]. The questionnaire was divided into seven sections containing 71 questions in total:
1.
Demographic data (age, gender, education, marital status, religion, number of children, type and time of cancer diagnosis, cancer treatment and lay-etiologic concepts)
2.
General self-efficacy scale
3.
Patient Activation Measure
4.
Complementary medicine (interest in, aims with and usage of complementary medicine sources of information)
5.
Importance and satisfaction with information the patients got about their disease.
Anzeige
The questionnaire included different types of questions, such as closed, multiple choice as well as 4-point and 5-point Likert scales questions.
The anonymous questionnaire was distributed as print version.
Patients
We included adult patients (≥ 18 years) with cancer attending an oncological outpatient clinic for the pilot study and patients attending a series of lectures on complementary medicine in different regions of Germany.
Statistical analysis
Exporting data was managed using Excel 2019. We utilized IBM SPSS Statistics 27 for data collection and analysis. To analyze associations between variables, chi-square tests were used and p values smaller than 0.05 were considered significant.
Ethics vote
Participation was voluntary and had no influence on the counseling on CAM or treatment. Written informed consent was given by filling in the questionnaire. The survey was accepted by an ethics committee.
Results
Demographic data
In total, 880 patients were addressed and 639 patients filled in the questionnaire (responsive rate: 72.6%, see Table 1). A third of the participants were male (32.9%) and two-thirds were female (63.2%). The leading cancer types were breast and gynecological cancer (41%), followed by gastrointestinal (19.2%) and urogenital cancer (15.6%).
Table 1
Demographic data (N = 639)
Category
Answer
n (%)
Gender
Male
210 (32.9)
Female
404 (63.2)
No answer
25 (3.9)
Age
< 30 years
4 (0.6)
31–50 years
79 (12.4)
51–70 years
388 (60.7)
71–80 years
127 (19.9)
> 80 years
39 (6.1)
No answer
2 (0.3)
Education
Secondary school qualification
366 (57.3)
High school graduation
48 (7.5)
University diploma
184 (28.8)
No answer
41 (6.4)
Type of cancer
Breast and gynaecological cancer
262 (41)
Gastrointestinal cancer
123 (19.2)
Urogenital cancer
100 (15.6)
Others (head-neck, skin, brain, thyroid)
62 (9.7)
Haemato-oncological cancer
40 (6.3)
Lung cancer
36 (5.6)
No answer
16 (2.5)
CAM usage and goals with CAM
Nearly two-thirds of the patients reported already using CAM (294 of 484; 60.7%). The majority used CAM in order to strengthen the forces of their body (82.3%) or the immune system (78%). Improvement of well-being (58.7%) and detoxification (27.4%) were further reasons. Less than a fifth used CAM for healing cancer (18.4%). In contrast, reducing side effects, coping with mental stress, or supporting conventional medicine were only a goal for 6.1% of the CAM users. Detailed data are reported in Ciarlo et al. [8].
The categories of CAM methods that were most often used included biologically based (73.2%), whole medical system (63.1%), and mind–body methods (62%) (see Fig. 1).
Fig. 1
Usage of CAM (N = 355; multiple answers were possible), *low carb, ketogenic, vegan, Budwig, Breuss
×
Anzeige
Self-efficacy and patient activation measure
Overall, 601 (98.0%) participants answered all items of the self-efficacy scale (M = 3.99; SD = 0.752) and 627 (97.8%) answered all items of the patient activation measure (M = 67.91; SD = 18.27). Detailed data are reported in Welter et al. [9].
Higher self-efficacy was associated with higher interest in CAM (p = 0.03). Yet, patients with higher self-efficacy do not use CAM more often than those with lower self-efficacy (p = 0.099). Some goals with CAM are associated with a higher self-efficacy. These goals are strengthening one’s own forces (p = 0.035), healing of the cancer (p = 0.008), or to do something for oneself (p = 0.039). Considering the methods used, patients with higher self-efficacy more often use homeopathy (p = 0.035), prayer (p = 0.040), or relaxation (p = 0.018). Yet, there was no association to meditation, yoga, or biologically based methods with the exception of vegan diet (p = 0.030). Also for cancer diets (low carb, ketogenic, Budwig or Breuss), there was no association.
Higher patient activation was associated with higher interest in CAM (p = 0.004) and usage of CAM (p = 0.012). Considering the different goals, no association was found to patient activation. With respect to CAM methods, patients with higher activation significantly more often reported using homeopathy (p = 0.007), prayer (p = 0.002), Yoga (p = 0.032), meditation (p = 0.002), low carb or ketogenic diets (p < 0.001) (but not vegan or other cancer diets).
Discussion
CAM usage is high in cancer patients and the type of CAM used was similar to former surveys with a preponderance of biologically based methods, mostly micronutrients [9]. Main goals for using CAM were strengthening the forces of the own body or the immune system. These goals are similar to former surveys [2, 3] even on an international level [10‐12]. These goals may be categorized as general goals in contrast to specific ones as reducing side effects. This was also reported by Wode and colleagues [12]. In line with this, two studies report a higher self-efficacy in patients in mind–body intervention groups [13, 14]. Moreover, patients turn to mind–body methods which often aim at improving well-being [15].
Anzeige
In contrast, reduction of side effects was named only by a small minority. Also Koenig et al. reported an improvement of tolerability to be a less important goal [16]. Accordingly, we have a contrast between patients’ needs and the endpoints in most clinical studies on biological-based CAM which aim at specific side effects.
Another important point in this context is that higher self-efficacy goes along with a higher effect of alternative treatments as Reiki which depend on a high placebo effect [17]. In fact, this would also explain the affinity of high self-efficacious patients to homeopathy.
Considering patient activation, a higher activation is associated with higher interest in CAM and usage of CAM. We found a broad range of methods being associated with higher activation which are quite similar to the methods used by patients with higher self-efficacy. Yet, considering the different goals, no association was found to patient activation. Loquai et al. have shown that patients using CAM are more likely to be physically active and to look for psychosocial support or contact to self-help [18]. Accordingly, Hibbard et al. reported higher activation in patients better coping with side effects [19].
All in all, a strategy to discuss CAM with cancer patients may be to start with agreeing on the goals before discussing special CAM methods. Moreover, patients attitude and needs for holistic (mind, body, soul) care should be addressed. Considering these goals and attitudes, patients should be referred to the best matching methods for which respective endpoints have been studied.
Anzeige
Limitation
The most important limitation of our survey is the recruitment of the patients as we addressed participants of lectures on CAM. Thus, interest in CAM has to be expected to be high. Yet, the rate of CAM users is nearly in line with recent German data [1, 3, 20].
Conclusion
Physicians might focus on patient activation as a goal in patient–physician relationship which will help patients to adhere to a healthy lifestyle and to participate in the whole treatment process.
Also, self-efficacy may entail positive effects if it is directed on goals such as coping with cancer and distress which may improve quality of life [17, 21, 22]. Providing information on mind–body techniques or self-help group participation may focus these patients on beneficial activities [23].
Declarations
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Ethical approval
The study was approved by the ethics committee of the university hospital at Jena.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent to publish
Not applicable.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.
Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.
Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.
Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
